As demonstrated above (Figure 8), this system could be employed to assess SARS-CoV-2 inhibitors and evaluate the neutralizing activity of convalescent antisera and anti-S protein mAbs; anti-S protein antibodies may be useful in treating critically ill COVID-19 patients. This evidence concerns the gene PROS1 and COVID-19.